Basic Information

Gene symbol HSPB1 Synonyms CMT2F, HEL-S-102, HMN2B, HMND3, HS.76067, HSP27, HSP28, Hsp25, SRP27 Type of gene protein-coding
Description heat shock protein family B (small) member 1

GTO ID GTC0038
Trial ID NCT00487786
Disease Prostate Cancer
Altered gene Hsp27
Therapeutic/Target gene Target gene
TherapyASO
Treatment OGX-427|Apatorsen
Co-treatment Docetaxel
PhasePhase1
Recruitment statusCompleted
TitleA Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27)
Year2007
CountryUnited States|Canada
Company sponsorAchieve Life Sciences
Other ID(s)OGX-427-01
Vector information
VectorNo vector was used

Clinical Result

Cohort1: dose level 1
Administration route infusion
Dosage 200 mg, once a week until withdrawn
Pts 6
Age Adult, Older_Adult
Adverse reactions No serious clinical adverse events
References PMID: 27022067
Cohort2: dose level 2
Administration route infusion
Dosage 400 mg, once a week until withdrawn
Pts 7
Age Adult, Older_Adult
Adverse reactions No serious clinical adverse events
References PMID: 27022067
Cohort3: dose level 3
Administration route infusion
Dosage 600 mg, once a week until withdrawn
Pts 7
Age Adult, Older_Adult
Adverse reactions 1/7(Infusion-related reaction); 1/7(Chills); 1/7(Pruritus); 1/7(Cytokine release syndrome); 1/7(Fatigue); 1/7(Urticaria); 1/7(Cerebral hemorrhage)
References PMID: 27022067
Cohort4: dose level 4
Administration route infusion
Dosage 800 mg, once a week until withdrawn
Pts 8
Age Adult, Older_Adult
Adverse reactions 1/8(Chills); 1/8(Cytokine release syndrome); 1/8(Blood creatinine increased); 1/8(Thrombocytopenia)
References PMID: 27022067
Cohort5: dose level 5
Administration route infusion
Dosage 1000 mg, once a week until withdrawn
Pts 14
Age Adult, Older_Adult
Adverse reactions 1/14(Hypokalemia); 1/14(Electrocardiogram Qt prolonged); 1/14(Oxygen saturation decreased)
References PMID: 27022067

Relationship Graph

Overview of Knowledge Graph